A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

D.R. Horton (NYSE: DHI), the largest U.S. homebuilder by volume, has taken investors on a roller-coaster ride over the last ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Biohaven (NYSE:BHVN) with a Buy recommendation.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Ubrelvy and Nurtec are prescription medications taken to treat migraines. Though they share similarities, Ubrelvy is for ...